SCHEDULE: BriaCell: Individual Discloses 100% Stake in '13G' Class

An individual investor, Jeremy Myung Jae Plambeck, has filed a Schedule 13G disclosing beneficial ownership of BriaCell Therapeutics Corp. securities, including common shares, warrants, and rights, totaling 13,638.61 common shares, which the filing states represents 100% of the '13G' class of securities.

Summary

• Jeremy Myung Jae Plambeck reported beneficial ownership of BriaCell Therapeutics Corp. securities, identified by CUSIP 10778Y104.
• The ownership includes 4,329.719 common shares.
• It also includes 2,995.6 common shares issuable upon exercise of 29,956 warrants (BCTXW) at a 10:1 exercise ratio.
• Additionally, 6,313.29 common shares are issuable upon conversion of 63,132.88 rights (BCTXZ) at a 10:1 conversion ratio.
• The total aggregate beneficial ownership is stated as 13,638.61 common shares in Item 4, though row 9 of the Schedule 13G form indicates 13,338.61 shares.
• The filing states this aggregate amount represents 100% of the '13G' class of securities.
• The reporting person has sole voting power over 4,329.72 shares and sole dispositive power over 4,329.72 shares, with shared voting and dispositive power reported as 0.00 shares.
• The reporting person is a citizen of Kansas, United States.

Sentiment

Score: 5

Explanation: The filing is primarily a factual disclosure of beneficial ownership. While it contains minor administrative delays and an internal inconsistency regarding the total share count and the '100% of class' claim, these issues are not severe enough to significantly alter the overall neutral sentiment for a standard ownership report.

Negatives

• Warrant (BCTXZ) conversion updates were not processed until September 5, 2025, despite the event date being August 25, 2025.
• Warrant (BCTXW) conversion updates were not processed until September 11, 2025, despite the event date being August 25, 2025.
• There is an inconsistency in the reported aggregate beneficial ownership, with 13,638.61 common shares detailed in Item 4 versus 13,338.61 shares stated in row 9.

Risks

• Operational inefficiencies or administrative delays in processing security conversions could impact shareholder records and transparency.

Stakeholder Impact

• Shareholders: The individual shareholder, Jeremy Myung Jae Plambeck, is directly impacted by the beneficial ownership and the administrative delays in updating their security conversions.
• Company Administration: BriaCell Therapeutics Corp.'s investor relations and transfer agents (Fidelity Investors, ComputerShare US, ComputerShare Canada) are implicated in the delays regarding warrant and right updates, suggesting potential administrative inefficiencies.

Key Dates

Keywords

BriaCell Therapeutics, SEC filing, Schedule 13G, beneficial ownership, warrants, rights, common shares, biotechnology